Nurix Therapeutics Stock Forecast
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 22.73 0.00%
NRIX analyst consensus
Consensus (14 analysts)
none
Avg. price target
$33.93+49.27%
- Strong buy 5
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 14 Wall Street analysts covering Nurix Therapeutics (2026-10-07), 13 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $33.93, with a high estimate of $45.00 and a low estimate of $25.00. The average target implies upside of 49.3% from the current price of $22.73.
The spread between the highest and lowest targets is 80.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NRIX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 5 | 36% |
| Buy | 8 | 57% |
| Hold | 1 | 7% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $25.00 | +9.99% |
| Average target | $33.93 | +49.27% |
| High target | $45.00 | +97.98% |